Virtual Event | November 7, 2023

Are We There Yet? Roadmap(s) To Higher Quality AAV

Source: Cytiva

Current limitations in AAV gene therapy manufacturing platforms often leave us making difficult tradeoffs between achieving the speed, flexibility, scale, and quality we ultimately need. To learn how current companies are evaluating and striving to overcome these tradeoffs in their technology and outsourcing partner selections, facility designs, and regulatory preparations, tune into this archived episode of Cell & Gene Live.

Anna Rose Welch, Director of Cell & Gene Collaborative, Craig Malzahn, Sr. Vice President of Technical Operations at REGENXBIO, and Andrew Tustian, Sr. Director - Viral Production Core at Regeneron, discussed what the AAV gene therapy space has learned about AAV quality so far and which quality-related advancements we’re on the brink of realizing in the near future.

access the Virtual Event!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene